External broker reports(aggregated public sources), Mirae Asset Securities

Mirae Asset Securities

Leading full-service brokerage firm in Vietnam. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>Promising batoclimab results heighten expectations for IMVT-1402Batoclimab demonstrates durable response at six months post-treatment At the 2025 American Thyroid Association annual meeting held in September, HanAll Biopharma’s US partner Immunovant announced promising six-month follow-up data for batoclimab in patients with Graves’ disease</li><li>Specifically, 17 of 21 patients (roughly 80%) showed a response and maintained normal thyroid function (T3 and T4 levels below the upper limit of normal) six months after discontinuing treatment</li><li>Notably, eight of the 17 responders (roughly 50%) achieved anti-thyroid drug (ATD)-free remission at six months post-treatment, indicating strong durability of response</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Promising batoclimab results heighten expectations for IMVT-1402Batoclimab demonstrates durable response at six months post-treatment At the 2025 American Thyroid Association annual meeting held in September, HanAll Biopharma’s US partner Immunovant announced promising six-month follow-up data for batoclimab in patients with Graves’ diseaseSpecifically, 17 of 21 patients (roughly 80%) showed a response and maintained normal thyroid function (T3 and T4 levels below the upper limit of normal) six months after discontinuing treatmentNotably, eight of the 17 responders (roughly 50%) achieved anti-thyroid drug (ATD)-free remission at six months post-treatment, indicating strong durability of responseContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

한올바이오파마(009420 KS/매수) 바토클리맙 유망한 결과, IMVT-1402에 대한 기대감 고조

Hanall Biopharma

한올바이오파마(009420 KS/매수) 바토클리맙 유망한 결과, IMVT-1402에 대한 기대감 고조